Bioxcel Therapeutics Logo
Igalmi_1500x450_select_corporate website banner

Innovative Medicine Backed by the Power of AI

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, approaches.

Innovative Medicine
Backed by the
Power of AI

BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques.

Innovative Medicine
Backed by the Power of AI

BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques.

Our Approach to Drug Development

AI-based Drug Development

Our neuroscience and immuno-oncology franchises utilize our AI
approach to drug development.

Neuroscience

BXCL501-Neuroscience-image
BXCL501 is an investigational, proprietary, orally dissolving, thin film formulation of dexmedetomidine designed for the treatment of agitation and opioid withdrawal symptoms.

Immuno-Oncology

BXCL701-Immuno-Oncology-image
BXCL701 is an investigational, orally-administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors.

Latest News

Jan 19, 2022
BioXcel Therapeutics Appoints Matt Wiley Chief Commercial OfficerVIEW RELEASE
Jan 04, 2022
BioXcel Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare ConferenceVIEW RELEASE
Dec 15, 2021
BioXcel Therapeutics Initiates Pivotal Phase 3 Program of BXCL501 for Acute Treatment of Agitation in Patients with Alzheimer’s DiseaseVIEW RELEASE

Stock Information

BioXcel Therapeutics, Inc.

Jan 21, 2022 04:00 PM

MARKET/SYMBOL

BTAI

PRICE

16.68

CHANGE

-0.75 (-4.3%)